Document is current
Any future updates will be listed below
-
Authors
Agrawal, Manasi https://orcid.org/0000-0003-4729-1485
Allin, Kristine H. https://orcid.org/0000-0002-6880-5759
Petralia, Francesca https://orcid.org/0000-0001-5096-9854
Colombel, Jean-Frederic https://orcid.org/0000-0001-6472-249X
Jess, Tine https://orcid.org/0000-0002-4391-7332
- License Information
-
More Information
Article History
Accepted: 21 February 2022
First Online: 17 March 2022
Competing interests
: M.A. is supported by the National Institute of Diabetes and Digestive and Kidney Diseases (K23DK129762-01). J.-F.C. has received research grants from AbbVie, Janssen Pharmaceuticals and Takeda; has received payment for lectures from AbbVie, Amgen, Allergan, Ferring Pharmaceuticals, Shire and Takeda; has received consulting fees from AbbVie, Amgen, Arena Pharmaceuticals, Boehringer Ingelheim, Bristol Myers Squibb, Celgene Corporation, Eli Lilly, Ferring Pharmaceuticals, Galmed Research, Glaxo Smith Kline, Geneva, Iterative Scopes, Janssen Pharmaceuticals, Kaleido Biosciences, Landos, Otsuka, Pfizer, Prometheus, Sanofi, Takeda and TiGenix; and holds stock options in Intestinal Biotech Development. K.H.A., F.P. and T.J. declare no competing interests.
